AAML1421, A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
Study ID: STU 042016-078
Summary
Primary objective of this study is to determine a recommended phase 2 dose (RP2D) and the toxicities associated with CPX-351 in pediatric and young adult patients with relapsed/refractory AML.